德国银行在收入和收入损失估计数之后,将和谐生物科学公司的价格目标削减到36美元。 Deutsche Bank cut Harmony Biosciences' price target to $36 after earnings and revenue missed estimates.

德国银行将其和谐生物科学(HRMY)的价格目标从54美元降低到36美元,保持“买入”评级,因为该公司报告第二季度收入为每股0.68美元,低于78美元的估计数,收入为2亿49万美元,略低于预期的2.0437亿美元,尽管年收入增加16%。 Deutsche Bank lowered its price target for Harmony Biosciences (HRMY) to $36 from $54, keeping a "buy" rating, after the company reported second-quarter earnings of $0.68 per share, below the $0.78 estimate, and revenue of $200.49 million, slightly under the $204.37 million expected, despite a 16% year-over-year revenue gain. 股票开盘量为27.51美元,交易额低于关键移动平均数,市场上限为15.8亿美元,物价与收益比率为8.87。 The stock opened at $27.51, trading below key moving averages, with a market cap of $1.58 billion and a price-to-earnings ratio of 8.87. 分析员维持“买入”共识,目标是45.50美元,预计2025年EPS为2.43美元。 Analysts maintain a "buy" consensus with a target of $45.50, projecting 2025 EPS of $2.43. 该公司将WAKIX出售给精神病患者,其债务与股本比率为0.20, 多数为机构所有。 The company, which markets WAKIX for narcolepsy, has a debt-to-equity ratio of 0.20 and is majority-owned by institutions.